1Du ZD, Zhang TH, Li T, et al. Ep idemiologic pictures of Kawasaki disease in Beijing from 1995 through 1999 [ J]. Pediat Infect Dis J, 2002, 21 (2): 103-107.
3Maisel AS , McCord J , Nowak RM , et al. Bedside B-Type natriuretic peptide in the emergency diagnosis of heart failure with reduced or preserved ejection fraction. Results from the breathing not properly muhinational study [ J]. J A m Coil Cardiol , 2003, 41(11):2010 -2017.
6Mir TS, Marohn S, Laer S, et al .Plasma concentrations of N terminal probrain natriurtic peptide in control children from the neonatal to adolescent period and in children with congestive heart failure[J].Pediat tics, 2002,110 (6) : 76.
7Laer S,Mir TS,Behn F, et al. Carvedilol therapy in pediatric patients with congestive heart failure: A study investigating clinical and pharmacokinetic parameters[J]. Am Heart J ,2002,143(5) :916-922.
8Bettencourt P. NT-proBNP and BNP: Biomarkers for heart failure management[J]. EurJ Heart Fail ,2004,6(3) :359 - 363.
9Cheng V, Kazanagra R, Garcia A, et al. A rapid bedside test for B-type peptide predicts treatment outcome in patients admitted for decompensated heart failure: A pilot study [J ]. J Am Coll Cardiol,2001,37:386-391.
10Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide(N-BNP) concentrations[ J ]. Lancet, 2000,355 : 1126 - 1130.
